Table 5.

Ocrelizumab phase II trial design.

	1st cycle (week 0)	2nd cycle (week 24)	3rd cycle (week 48)	4th cycle (week 72)
Treatment arm	Days 1, 15	Days 1, 15	Day 1	Day 1
1	OCR 300 mg, 300 mg	OCR 600 mg, placebo	OCR 600 mg	OCR 600 mg
2	OCR 1000 mg, 1000 mg	OCR 1000 mg, placebo	OCR 1000 mg	OCR 600 mg
3	Placebo	OCR 300 mg, 300 mg	OCR 600 mg	OCR 600 mg
4	IFN-β-1a 30 μg weekly	OCR 300 mg, 300 mg	OCR 600 mg	OCR 600 mg

Abbreviations: OCR, Ocrelizumab; IFN-β-1a, interferon-beta-1a.